Shenzhen Anjieming Medical Technology

Shenzhen Anjieming Medical Technology, established on October 13, 2021, is a medical technology company focused on the ophthalmology sector, particularly on developing solutions for the early diagnosis of glaucoma. The company originated as a joint venture spearheaded by a postdoctoral team from the Hong Kong University of Science and Technology (HKUST) and the National Innovation Center for High-Performance Medical Devices. The founding team includes CEO & CTO Qin臻, a Ph.D. and postdoctoral fellow from HKUST, who leads the company's mission to merge mechanical engineering with medical applications. Other key members are Chairman & CFO Zhong Yutang, Software R&D Director Li Jingqian, and Product Technology Director Ke Bingwei.

Anjieming Medical operates in the medical device market, providing diagnostic tools to healthcare institutions like hospitals and research centers. The company's business model centers on the research, development, and commercialization of advanced ophthalmic diagnostic equipment. Its strategic direction aligns with China's "14th Five-Year National Eye Health Plan (2021-2025)". The company has secured significant funding to advance its objectives, including a nearly ten million RMB angel round in November 2022 and a multi-million RMB Pre-A round in November 2024, which will be used for clinical trials, market entry, and team expansion.

The company is developing two primary products aimed at addressing the challenges of glaucoma, known as the "silent killer of sight". The first is the Corneal Biomechanical Analysis System, which performs in-vivo dynamic measurements of the cornea's biomechanical properties. This system utilizes a contact-based dynamic analysis algorithm to provide a more accurate intraocular pressure reading, which is crucial for assessing glaucoma risk. The second key product is a 24-hour Continuous Intraocular Pressure Monitoring System, a non-invasive device designed as a soft contact lens. This system enables all-day, real-time monitoring of eye pressure fluctuations, overcoming the limitations of traditional single-point measurements, especially for capturing pressure spikes that often occur at night. This technology aims to provide a comprehensive dataset for the early diagnosis and treatment evaluation of glaucoma.

Keywords: ophthalmic diagnostics, glaucoma early diagnosis, medical devices, corneal biomechanics, intraocular pressure monitoring, eye health, medtech, HKUST, Qin Zhen, continuous monitoring system, non-invasive diagnostics, eye care technology, National Innovation Center for High-Performance Medical Devices, vision health, ophthalmology technology, medical engineering, diagnostic systems, angel investment, Pre-A funding